Vaxart, Inc. (VXRT)
NASDAQ: VXRT · Real-Time Price · USD
0.4000
-0.0155 (-3.73%)
May 14, 2025, 10:16 AM - Market open
Vaxart Revenue
Vaxart had revenue of $20.88M in the quarter ending March 31, 2025, with 857.18% growth. This brings the company's revenue in the last twelve months to $47.40M, up 433.43% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
$47.40M
Revenue Growth
+433.43%
P/S Ratio
1.90
Revenue / Employee
$451,381
Employees
105
Market Cap
91.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
| Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
| Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
| Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
| Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VXRT News
- 13 hours ago - Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 18 hours ago - Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 18 hours ago - Vaxart Appoints Jeroen Grasman as Chief Financial Officer - GlobeNewsWire
- 2 days ago - Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement - GlobeNewsWire
- 9 days ago - Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress - GlobeNewsWire
- 12 days ago - Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13 - GlobeNewsWire
- 14 days ago - Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate - GlobeNewsWire
- 4 weeks ago - Vaxart to Present at World Vaccine Congress Washington 2025 on April 23 - GlobeNewsWire